Statistik Asas
| LEI | 5299008YP2BW4570ML28 |
| CIK | 1600620 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aurinia Pharmaceuticals Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 31, 2025 |
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 ROCKVILLE, Maryland and EDMONTON, Alberta – July 31, 2025 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2025. Financial Results •Total Revenue: For the three and six months ended June 30, 2025, total revenue wa |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 30, 2025 |
June 30, 2025 Aritinercept (AUR200) A Dual BAFF/APRIL Inhibitor for the Potential Treatment of Autoimmune Diseases Results from a Phase 1 Study Forward-Looking Statements This presentation contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U. |
|
| June 30, 2025 |
Exhibit 99.1 Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Dosing Plan to Initiate Clinical Studies in at Least Two Autoimmune Diseases in the Second Half of This Year Aurinia to Host Conference Call Today, June 30, at 8:30 a. |
|
| May 16, 2025 |
Calculation of Filing Fee Tables S-8 Aurinia Pharmaceuticals Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common shares no par value 457(a) 6,000,000 $ 7.72 $ 46,320,000.00 0.0001531 $ 7,091.59 Total Offering A |
|
| May 16, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 16, 2025 As filed with the U.S. Securities and Exchange Commission on May 16, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 98-1231763 (State or other jurisdiction of incorporation or organiz |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (C |
|
| May 15, 2025 |
Purpose AURINIA PHARMACEUTICALS INC. (the “Company”) EQUITY INCENTIVE PLAN AS AMENDED AND RESTATED AS OF MAY 15, 2025 Article 1 PURPOSE AND INTERPRETATION Exhibit 99.1 1.1 The purpose of the Plan is to advance the interests of the Company by encouraging equity participation in the Company through the acquisition of Common Shares of the Company. It is the intention of the Company that this Plan wil |
|
| May 15, 2025 |
Amended and Restated By-Law No. 2 Exhibit 3.1 BY-LAW NO. 2 AN AMENDED AND RESTATED GENERAL OPERATING BY-LAW AURINIA PHARMACEUTICALS INC. hereinafter called “the Corporation” SECTION 1 INTERPRETATION 1.1 Definitions In the By-laws of the Corporation, unless the context otherwise requires: “Act” means the Business Corporations Act of Alberta, and any statute that may be substituted therefor, as from time to time amended; “appoint” i |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2025 |
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 ROCKVILLE, Maryland and EDMONTON, Alberta – May 12, 2025 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results •Total Revenue: For the three months ended March 31, 2025, total revenue was $ |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| February 27, 2025 |
List of Subsidiaries of Registrant Exhibit 21.1 LIST OF SUBSIDIARIES The following is a list of subsidiaries of Aurinia Pharmaceuticals Inc. as of December 31, 2024. Subsidiary State or Other Jurisdiction of Incorporation or Organization Aurinia Pharma U.S., Inc. Delaware Aurinia Pharma Limited United Kingdom |
|
| February 27, 2025 |
Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress ROCKVILLE, Maryland and EDMONTON, Alberta – February 27, 2025 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2024 and provided an update on recent c |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals I |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 27, 2025 |
Exhibit 19.1 AURINIA PHARMACEUTICALS INC. Insider Trading Policy (Approved February 11, 2025) AURINIA PHARMACEUTICALS INC. INSIDER TRADING POLICY1 1.PURPOSE This Insider Trading Policy (the “Policy”) provides guidelines to all directors, officers and employees (“Company Personnel”) of Aurinia Pharmaceuticals Inc. and its subsidiaries (collectively, the “Company”) with respect to trading in the Com |
|
| November 14, 2024 |
AUPH / Aurinia Pharmaceuticals Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-auph093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aurinia Pharmaceuticals Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 05156V102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| November 7, 2024 |
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth Exhibit 99.2 Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth ROCKVILLE, Maryland and EDMONTON, Alberta – November 7, 2024 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth. Mr. Johnson has more than 3 |
|
| November 7, 2024 |
Exhibit 99.1 Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development •Achieved $67.8 million in total net revenue and $55.5 million in net product revenue for the third quarter of 2024, representing year-over-year growth of 24% and 36%, respectively |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| September 12, 2024 |
Aurinia Announces Board Restructuring Exhibit 99.1 Aurinia Announces Board Restructuring •Peter Greenleaf, President and Chief Executive Officer of Aurinia, remains a Director •Kevin Tang, President of Tang Capital Management, LLC, appointed as a Director •The Board has accepted the conditional resignations of three directors who received less than majority support at the 2024 Annual General Meeting ROCKVILLE, Md. & EDMONTON, Alberta |
|
| September 12, 2024 |
AUPH / Aurinia Pharmaceuticals Inc. / TANG CAPITAL MANAGEMENT LLC Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the securities exchange act of 1934 (amendment no. |
|
| September 12, 2024 |
Exhibit 3.1 BY-LAW NO. 2 AN AMENDED AND RESTATED GENERAL OPERATING BY-LAW AURINIA PHARMACEUTICALS INC. (“the Corporation”) Table of Contents SECTION 1 INTERPRETATION 1 SECTION 2 BUSINESS OF THE CORPORATION 2 SECTION 3 BORROWING AND SECURITIES 3 SECTION 4 DIRECTORS 3 SECTION 5 COMMITTEES 9 SECTION 6 OFFICERS 10 SECTION 7 INTEREST IN MATERIAL CONTRACTS AND PROTECTION OF DIRECTORS, OFFICERS AND OTHER |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporatio |
|
| August 1, 2024 |
AURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2024 FINANCIAL AND OPERATIONAL RESULTS Exhibit 99.1 AURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2024 FINANCIAL AND OPERATIONAL RESULTS •Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively •Company generated approximately $15.8 million in free cash flow in the second quar |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) ( |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| May 2, 2024 |
AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS Exhibit 99.1 AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS •Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and extending the trend of consistent growth in LUPKYNIS® (voclosporin) sales •Rapidly completed restructur |
|
| May 2, 2024 |
Agreement between Aurinia Pharma U.S. Inc. and Volker Knappertz dated Mar Exhibit 3.4 March 4, 2024 CONFIDENTIAL – NOT FOR DISCLOSURE VIA ELECTRONIC MAIL Volker Knappertz, M.D. [redacted] Re: Severance Agreement, Release, and Covenant Not To Sue Dear Volker: As we have discussed, your employment with Aurinia Pharma U.S., Inc. (“Corporation”) will terminate today, March 4, 2024 (“Termination Date”). Effective as of the Termination Date, you are to cease all efforts on be |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurin |
|
| March 20, 2024 |
Letter to Management and Board of Directors, dated March 20, 2024 Exhibit 99.1 To the Management and Board of Aurinia Pharmaceuticals Inc., As you know, ILJIN SNT Co., Ltd. (“ILJIN”) is a long-standing investor of Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”), with its first investment in Isotechnika (later merged with Aurinia) dating back to 2010. During the past 14 years, ILJIN has supported Aurinia’s efforts to secure FDA approval for Lupkynis, an |
|
| March 20, 2024 |
AUPH / Aurinia Pharmaceuticals Inc. / ILJIN SNT Co., Ltd. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13D-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 15) Aurinia Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 05156V102 (CUSIP Numb |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporatio |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 15, 2024 |
List of Subsidiaries of Registrant Exhibit 21.1 LIST OF SUBSIDIARIES The following is a list of subsidiaries of Aurinia Pharmaceuticals Inc. as of December 31, 2023. Subsidiary State or Other Jurisdiction of Incorporation or Organization Aurinia Pharma U.S., Inc. Delaware Aurinia Pharma Limited United Kingdom |
|
| February 15, 2024 |
Incentive Compensation Recoupment Policy Exhibit 97.1 Aurinia Pharmaceuticals Inc. Incentive Compensation Recoupment Policy (Approved November 22, 2023) 1. Introduction The Board of Directors (the “Board”) of Aurinia Pharmaceuticals Inc., an Alberta corporation (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providi |
|
| February 15, 2024 |
Exhibit 99.1 Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value •Total net revenue was $45.1 million and $175.5 million, and net product revenue was $42.3 million and $158.5 million, for the fourth quarter and full year 2023, respectively •$350.7 million of cash, cash equivalents, restricted cash and investments as |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals I |
|
| February 14, 2024 |
AUPH / Aurinia Pharmaceuticals Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-auph123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aurinia Pharmaceuticals Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 05156V102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 5, 2024 |
Exhibit 99.1 AURINIA PROVIDES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL-YEAR 2023 NET REVENUE RESULTS Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million Preliminary unaudited net product revenue for the fourth quarter and full year 2023 of approximately $42 million and $159 million Approximately $351 million of cash, |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| November 2, 2023 |
Exhibit 99.1 AURINIA PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS Net product revenue of $40.8 million for the third quarter of 2023; an increase of 60% over the prior year third quarter Total net revenue of $130.4 million for the nine months ended September 30, 2023, an increase of 24% over prior year Achieved European pricing and reimbursement mile |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 21, 2023 |
Exhibit 99.1 Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital EDMONTON, Alberta—September 21, 2023—Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together wi |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporati |
|
| September 21, 2023 |
Exhibit 10.1 EXECUTION VERSION COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), dated as of September 21, 2023 (the “Effective Date”), is by and among Aurinia Pharmaceuticals Inc. (the “Company”), and MKT Capital Ltd., MKT Tactical Fund, SP and Antoine Khalife (collectively, “MKT”). Capitalized terms in this Agreement shall have the meanings set forth in this Agreement. WHEREAS |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) |
|
| August 21, 2023 |
Exhibit 99.1 Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia’s Board of Directors August 18, 2023 Dr. Daniel G. Billen appointed Chair of the Board of Directors EDMONTON, Alberta—August 21, 2023—Aurinia Pharmaceuticals Inc. (N |
|
| August 3, 2023 |
Exhibit 99.1 AURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS Net revenue increased to $41.5 million for second quarter of 2023; 47% over the prior year second quarter Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS® (voclosporin) Conference call to be hosted today at 8:30 a.m. ET EDMONTON, Alberta |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Submitted Pursuant to Rule 14a-6(g) (Amendment No. ) 1. Name of the Registrant: Aurinia Pharmaceuticals Inc. 2. Name of Person Relying on Exemption: MKT Capital Ltd. 3. Address of Person Relying on Exemption: c/o Ogier Fiduciary Service (Cayman) Limited 89 Nexus Way, Camana Bay Grand Cayman, Cayma |
|
| July 3, 2023 |
Exhibit 99.1 Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value In Addition, Board has Accepted Recent Director Resignations and has Initiated a Search for New Directors EDMONTON, Alberta—June 29, 2023—Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has initiated an exploratio |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) ( |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Submitted Pursuant to Rule 14a-6(g) (Amendment No. ) 1. Name of the Registrant: Aurinia Pharmaceuticals Inc. 2. Name of Person Relying on Exemption: MKT Capital Ltd. 3. Address of Person Relying on Exemption: c/o Ogier Fiduciary Service (Cayman) Limited 89 Nexus Way, Camana Bay Grand Cayman, Cayma |
|
| May 26, 2023 |
As filed with the U.S. Securities and Exchange Commission on May 26, 2023 As filed with the U.S. Securities and Exchange Commission on May 26, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aurinia Pharmaceuticals Inc. (Exact name of Registrant as specified in its charter) Alberta, Canada 98-1231763 (State or other jurisdiction of Incorporation or organiz |
|
| May 26, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aurinia Pharmaceuticals Inc. |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Submitted Pursuant to Rule 14a-6(g) (Amendment No. ) 1. Name of the Registrant: Aurinia Pharmaceuticals Inc. 2. Name of Person Relying on Exemption: MKT Capital Ltd. 3. Address of Person Relying on Exemption: c/o Ogier Fiduciary Service (Cayman) Limited 89 Nexus Way, Camana Bay Grand Cayman, Cayma |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (C |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Submitted Pursuant to Rule 14a-6(g) (Amendment No. ) 1. Name of the Registrant: Aurinia Pharmaceuticals Inc. 2. Name of Person Relying on Exemption: MKT Capital Ltd. 3. Address of Person Relying on Exemption: c/o Ogier Fiduciary Service (Cayman) Limited 89 Nexus Way, Camana Bay Grand Cayman, Cayma |
|
| May 10, 2023 |
AUPH / Aurinia Pharmaceuticals Inc / ILJIN SNT Co., Ltd. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13D-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 14) Aurinia Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 05156V102 (CUSIP Numb |
|
| May 10, 2023 |
Letter to Board of Directors, dated May 10, 2023 Exhibit 99.1 Board of Directors of Aurinia, IUIN SNT Co., Ltd. is a shareholder holding approximately 4.3% of Aurinia's outstanding shares, and together with certain related companies, holding approximately 6.1% in aggregate. We have seen several promising start-ups with creativity and innovation in the U.S. and Canada, and began investing in Isotechnika before its merger with Aurinia in 2010. Ove |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Submitted Pursuant to Rule 14a-6(g) (Amendment No. ) 1. Name of the Registrant: Aurinia Pharmaceuticals Inc. 2. Name of Person Relying on Exemption: MKT Capital Ltd. 3. Address of Person Relying on Exemption: c/o Ogier Fiduciary Service (Cayman) Limited 89 Nexus Way, Camana Bay Grand Cayman, Cayma |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| May 4, 2023 |
Exhibit 99.1 AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATIONAL RESULTS $34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 - $155 million from net product sales of LUPKYNIS Significant progress across Commercial, R&D and Intellectual Property Conference call |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Submitted Pursuant to Rule 14a-6(g) (Amendment No. ) 1. Name of the Registrant: Aurinia Pharmaceuticals Inc. 2. Name of Person Relying on Exemption: MKT Capital Ltd. 3. Address of Person Relying on Exemption: c/o Ogier Fiduciary Service (Cayman) Limited 89 Nexus Way, Camana Bay Grand Cayman, Cayma |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Submitted Pursuant to Rule 14a-6(g) (Amendment No. ) 1. Name of the Registrant: Aurinia Pharmaceuticals Inc. 2. Name of Person Relying on Exemption: MKT Capital Ltd. 3. Address of Person Relying on Exemption: c/o Ogier Fiduciary Service (Cayman) Limited 89 Nexus Way, Camana Bay Grand Cayman, Cayma |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 5, 2023 |
Exhibit 99.1 Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial LUPKYNIS® treated patients showed histologic activity improvement with stable chronicity scores similar to active control arm of mycophenolate mofetil (MMF) and low dose steroids alone Data further reinforces differentiation of LUPKYNIS from first generation calcineurin inhibitors |
|
| April 5, 2023 |
finalrenalbiopsysub-stud Renal Biopsy Sub-study April 2023 indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN) Limitations of use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 28, 2023 |
Form of Restricted Stock Unit Award under the Equity Incentive Plan Exhibit 10.21 AURINIA PHARMACEUTICALS INC. RESTRICTED STOCK UNIT GRANT NOTICE (EQUITY INCENTIVE PLAN) AURINIA PHARMACEUTICALS INC. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU”). Your RSU is subject to all of the terms and conditions as set forth herein and in the C |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals I |
|
| February 28, 2023 |
Exhibit 99.1 AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND COMPANY UPDATES $28.4 million in total net revenue for the fourth quarter 2022, a 21% increase over fourth quarter 2021 and $134.0 million for full year 2022, a 194% increase over 2021 Cash, cash equivalents, and investments of $389.4 million as of December 31, 2022 Conference call to be hosted today at 8:30 a.m. |
|
| February 28, 2023 |
Form of Inducement Restricted Stock Unit Award Exhibit 10.20 AURINIA PHARMACEUTICALS INC. RESTRICTED STOCK UNIT GRANT NOTICE (EQUITY INCENTIVE PLAN) AURINIA PHARMACEUTICALS INC. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU”). This Initial Grant is intended to serve as an inducement for you to join the Company an |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 28, 2023 |
List of Subsidiaries of Registrant Exhibit 21.1 LIST OF SUBSIDIARIES The following is a list of subsidiaries of Aurinia Pharmaceuticals Inc. as of December 31, 2022. Subsidiary State or Other Jurisdiction of Incorporation or Organization Aurinia Pharma U.S., Inc. Delaware Aurinia Pharma Limited United Kingdom |
|
| February 14, 2023 |
AUPH / Aurinia Pharmaceuticals Inc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-auph123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aurinia Pharmaceuticals Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 05156V102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 7, 2023 |
AUPH / Aurinia Pharmaceuticals Inc / BlackRock Inc. Passive Investment ca05156v1022020723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Aurinia Pharmaceuticals Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) BFWLC09 - (SEDOL Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 20, 2023 |
AUPH / Aurinia Pharmaceuticals Inc / ILJIN SNT Co., Ltd. - SC 13D/A Activist Investment SC 13D/A 1 tm232472d2sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13D-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 13) Aurinia Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of C |
|
| January 9, 2023 |
AURINIA PROVIDES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL-YEAR 2022 NET REVENUE RESULTS Preliminary unaudited net revenue for the fourth quarter and full year 2022 of approximately $28. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 6, 2023 |
AUPH / Aurinia Pharmaceuticals Inc / ILJIN SNT Co., Ltd. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ?240.13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ?240.13D-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 12) Aurinia Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 05156V102 (CUSIP Numb |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 3, 2022 |
Separation Agreement between Aurinia Pharmaceuticals Inc. and Neil Solomons dated October 20, 2022 Exhibit 10.25 PERSONAL AND CONFIDENTIAL October 20, 2022 Neil Solomons [redacted] Dear Neil: Re: End of Employment with Aurinia Pharmaceuticals Inc. (the “Company”) Further to our recent discussions, as you are aware, the Company wished for you to begin to report to Volker Knappertz, Executive Vice President, Research and Development, pursuant to your current terms and conditions of employment (in |
|
| November 3, 2022 |
Exhibit 99.1 AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS Net revenue of $55.8 million for Q3 2022; including $30.0 million milestone from Otsuka related to European Approval of LUPKYNIS® (voclosporin) Adjusts net product revenue guidance to $100-105 million from sales of LUPKYNIS for 2022 Issues preliminary net product revenue guidance for 2023 in the range |
|
| November 3, 2022 |
Separation Agreement between Aurinia Pharmaceuticals Inc. and Rob Huizinga dated October 20, 2022 Exhibit 10.26 PERSONAL AND CONFIDENTIAL October 20, 2022 Robert B. Huizinga [redacted] Dear Rob: Re: End of Employment with Aurinia Pharmaceuticals Inc. (the “Company”) Further to our recent discussions, as you are aware, the Company wished for you to assume the role of Senior Vice President, Medical Affairs, pursuant to your current terms and conditions of employment (including with respect to co |
|
| November 3, 2022 |
Separation Agreement between Aurinia Pharma U.S. Inc. and Max Colao dated Exhibit 10.24 CONFIDENTIAL SEPARATION AGREEMENT, GENERAL RELEASE AND COVENANT NOT TO SUE This is a Confidential Separation Agreement, General Release and Covenant Not to Sue (“Agreement”) between Aurinia Pharma U.S., Inc. (“Aurinia”), on the one hand, and Max Colao (“Mr. Colao”), on the other hand. Aurinia and Mr. Colao shall collectively be referred to herein as the “Parties”. WHEREAS, Mr. Colao |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| October 28, 2022 |
AUPH / Aurinia Pharmaceuticals Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 4, 2022 |
Employment Agreement between Aurinia Pharma U.S. Inc., and Scott Habig dated June 27, 2022 Exhibit 10.23 EMPLOYMENT AGREEMENT AURINIA PHARMA U.S., INC. PRIVATE AND CONFIDENTIAL June 27, 2022 Scott Habig [redacted] Re: Terms of Employment with Aurinia Pharma U.S., Inc. Dear Scott: This Employment Agreement (?Agreement?) sets forth the terms and conditions of your employment with Aurinia Pharma U.S., Inc. (the ?Corporation?), a Delaware corporation and wholly owned subsidiary of Aurinia P |
|
| August 4, 2022 |
Exhibit 10.46 SUPPLY AGREEMENT by and between AURINIA PHARMACEUTICALS INC. and OTSUKA PHARMACEUTICAL CO., LTD. AUGUST 1, 2022 Table of Contents Article 1 Interpretation 1 1.1 Commercial Supply under Collaboration Agreement 1 1.2 Priority 2 1.3 Collaboration Agreement Definitions 2 1.4 Local Definitions 2 1.5 Applicable Terms of the Collaboration Agreement 5 Article 2 Manufacture and Supply 5 2.1 G |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 4, 2022 |
Exhibit 10.22 EMPLOYMENT AGREEMENT AURINIA PHARMA U.S., INC. PRIVATE AND CONFIDENTIAL July 11, 2022 Volker Knappertz, M.D. [redacted] Re: Terms of Employment with Aurinia Pharma U.S., Inc. Dear Dr. Knappertz: This Employment Agreement (?Agreement?) sets forth the terms and conditions of your employment with Aurinia Pharma U.S., Inc. (the ?Corporation?), a Delaware corporation and wholly owned subs |
|
| August 4, 2022 |
Exhibit 99.1 AURINIA REPORTS SECOND QUARTER AND SIX MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS Net revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS® (voclosporin) for 2022 Continued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Coverage EMA review of LUPKYNIS remains on track with de |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2022 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) ( |
|
| May 20, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (C |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 98-1231763 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 10, 2022 |
Exhibit 99.1 AURINIA REPORTS FIRST QUARTER 2022 FINANCIAL AND OPERATIONAL RESULTS $21.6 million in net revenue for Q1 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS for 2022 Continued increases in LUPKYNIS? (voclosporin) Patients on Treatment and Patient Start Forms; Steady Conversion Rates and Payor Coverage EMA review of LUPKYNIS remains on track with deci |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 3, 2022 |
AUPH / Aurinia Pharmaceuticals Inc / ILJIN SNT Co., Ltd. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ?240.13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ?240.13D-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 11) Aurinia Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 05156V102 (CUSIP Numb |
|
| February 28, 2022 |
List of Subsidiaries of Registrant Exhibit 21.1 LIST OF SUBSIDIARIES The following is a list of subsidiaries of Aurinia Pharmaceuticals Inc. as of December 31, 2021. Subsidiary State or Other Jurisdiction of Incorporation or Organization Aurinia Pharma U.S., Inc. Delaware Aurinia Pharma Limited United Kingdom |
|
| February 28, 2022 |
Exhibit 99.1 AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND COMPANY UPDATES $23.4 million in net revenue for the fourth quarter 2021 (60% increase from third quarter) and $45.6 million in net revenue for full year 2021 2021 readout of strong results from AURORA 2 continuation study fuels momentum for year two of launch Cash and cash equivalents, and investments of $466.1 m |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals I |
|
| February 14, 2022 |
AUPH / Aurinia Pharmaceuticals Inc / HealthCor Management, L.P. - SC 13G/A Passive Investment SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2)* Aurinia Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05156V102 (CUSIP Number) December 31, 2021 (Date of Event Which Requ |
|
| February 14, 2022 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| January 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 7, 2022 |
EX-99.1 2 aurora2clinicalprogramir.htm EX-99.1 CLINICAL PROGRAM UPDATE AURORA 2 / voclosporin Updated January 2022 AURORA 2 demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy AURORA 2 Readout Results AURORA 2 Study Design AURORA 1 (n=357) One-Year Study AURORA 2 (n=216) Two-Year Study • AURORA 2 is a Phase 3, global, d |
|
| December 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 9, 2021 |
CLINICAL PROGRAM UPDATE AURORA 2 / voclosporin December 9, 2021 AURORA 2 demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy AURORA 2 Readout Results AURORA 2 Study Design AURORA 1 (n=357) One-Year Study AURORA 2 (n=216) Two-Year Study ? AURORA 2 is a Phase 3, global, double-blind, two-year continuation study of AURORA |
|
| November 19, 2021 |
Exhibit 4.3 Aurinia Pharmaceuticals Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate |
|
| November 19, 2021 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.6 AURINIA PHARMACEUTICALS INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF AURINIA PHARMACEUTICALS INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between AURINIA PHARMACEUTICALS INC., an Alberta corporation (the ?Company?), and [?], a [corporation] [national banking association] o |
|
| November 19, 2021 |
Power of Attorney (see signature pages) S-3ASR 1 d241350ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 19, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Alberta, Canada 46-4129078 (Sta |
|
| November 19, 2021 |
EX-1.2 2 d241350dex12.htm EX-1.2 Exhibit 1.2 AURINIA PHARMACEUTICALS INC. (existing under the Business Corporations Act (Alberta)) Controlled Equity OfferingSM November 19, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Aurinia Pharmaceuticals Inc., a company existing under the Business Corporations Act (Alberta) (the “Company”), confirms its agreement (this |
|
| November 19, 2021 |
Form of Common Shares Warrant Agreement and Warrant Certificate Exhibit 4.5 AURINIA PHARMACEUTICALS INC. AND , AS WARRANT AGENT FORM OF COMMON SHARES WARRANT AGREEMENT DATED AS OF AURINIA PHARMACEUTICALS INC. FORM OF COMMON SHARES WARRANT AGREEMENT THIS COMMON SHARES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between AURINIA PHARMACEUTICALS INC., an Alberta corporation (the ?Company?), and [?], a [corporation] [national banking association] organiz |
|
| November 3, 2021 |
Exhibit 99.1 AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2021 FINANCIAL RESULTS AND COMPANY UPDATES $14.7 million in net revenue for the third quarter 2021 (122% increase from second quarter 2021) Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage Addition of two preclinical assets with potential in rare autoimmune conditions to grow and diversify the pipeline |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 17, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 17, 2021 |
Exhibit 99.1 Confidential Riptide Aurinia Collaboration & License Agreement Between Aurinia Pharmaceuticals Inc. and Riptide Bioscience, Inc. Effective Date: August 16, 2021 Certain identified information has been excluded from this document because it is both (i) not material; and (ii) would be competitively harmful if publicly disclosed. 2 Riptide Aurinia Collaboration & License Agreement Summar |
|
| August 5, 2021 |
Exhibit 99.1 AURINIA REPORTS SECOND QUARTER AND SIX MONTHS 2021 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS ?$6.6 million in net revenue for the second quarter 2021 (624% increase from first quarter 2021) ? ?415 patient start forms (PSFs) received for LUPKYNISTM during the second quarter (over a 60% increase from the first quarter 2021) and over 800 PSFs received year-to-date - ?Continued |
|
| August 5, 2021 |
Exhibit 99.1 AURINIA REPORTS SECOND QUARTER AND SIX MONTHS 2021 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS ?$6.6 million in net revenue for the second quarter 2021 (624% increase from first quarter 2021) ? ?415 patient start forms (PSFs) received for LUPKYNISTM during the second quarter (over a 60% increase from the first quarter 2021) and over 800 PSFs received year-to-date - ?Continued |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| July 19, 2021 |
Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange Exhibit 99.1 Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange VICTORIA, British Columbia ? July 16, 2021 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company), a commercial stage biopharmaceutical company advancing therapies for severe autoimmune diseases, announced today it will voluntarily delist the common shares of the Company from the Tor |
|
| July 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 25, 2021 |
Aurinia Pharmaceuticals Inc. 2021 Employee Share Purchase Plan S-8 1 auph-2021junesx8eipandespp.htm S-8 As filed with the U.S. Securities and Exchange Commission on June 25, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aurinia Pharmaceuticals Inc. (Exact name of Registrant as specified in its charter) Alberta, Canada 46-4129078 (State or othe |
|
| June 25, 2021 |
Exhibit 99.1 Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA) VICTORIA, British Columbia and ROCKVILLE, Maryland ? June 25, 2021 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) announced today that the Company?s licensing partner, Otsuka Pharmaceutical Europe Ltd. (OPEL |
|
| June 25, 2021 |
Aurinia Pharmaceuticals Inc. Amended and Restated Equity Exhibit 10.1 AURINIA PHARMACEUTICALS INC. (the ?Company?) EQUITY INCENTIVE PLAN AS AMENDED AND RESTATED AS OF JUNE 7, 2021 ARTICLE 1 PURPOSE AND INTERPRETATION Purpose 1.1 The purpose of the Plan is to advance the interests of the Company by encouraging equity participation in the Company through the acquisition of Common Shares of the Company. It is the intention of the Company that this Plan wil |
|
| June 25, 2021 |
Aurinia Pharmaceuticals Inc. 2021 Employee Share Purchase Plan Exhibit 10.2 Aurinia Pharmaceuticals Inc. 2021 Employee Share Purchase Plan 1.General; Purpose. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase Shares. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Share Purchase Plan. In addition, |
|
| June 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 AURINIA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 17, 2021 |
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors Exhibit 99.1 Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors VICTORIA, British Columbia ? June 14, 2021 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company?s board of directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corpor |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 10, 2021 |
AURINIA PHARMACEUTICALS INC. 2021 EMPLOYEE SHARE PURCHASE PLAN Exhibit 99.2 AURINIA PHARMACEUTICALS INC. 2021 EMPLOYEE SHARE PURCHASE PLAN 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase Shares. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Share Purchase Plan. In addition |
|
| June 10, 2021 |
EX-99.1 2 a9912021auriniaamendedandr.htm EX-99.1 Exhibit 99.1 AURINIA PHARMACEUTICALS INC. (the “Company”) EQUITY INCENTIVE PLAN AS AMENDED AND RESTATED AS OF JUNE 7, 2021 ARTICLE 1 PURPOSE AND INTERPRETATION Purpose 1.1 The purpose of the Plan is to advance the interests of the Company by encouraging equity participation in the Company through the acquisition of Common Shares of the Company. It i |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 6, 2021 |
Exhibit 99.1 AURINIA REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS - Quarter highlights include FDA approval, launch and early market penetration of LUPKYNISTM as the first approved oral therapy for lupus nephritis (LN) ? -Over 250 patient start forms received by the end of the first quarter - - Cash and cash equivalents, and investments of $360.9 million at March |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals Inc. |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurin |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 27, 2021 |
BY-LAW NO. 2 AN AMENDED AND RESTATED GENERAL OPERATING BY-LAW AURINIA PHARMACEUTICALS INC. hereinafter called ?the Corporation? SECTION 1 INTERPRETATION 1.1 Definitions In the By-laws of the Corporation, unless the context otherwise requires: ?Act? means the Business Corporations Act of Alberta, and any statute that may be substituted therefor, as from time to time amended; ?appoint? includes ?ele |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 11, 2021 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aurinia Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 05156V102 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842- |
|
| February 24, 2021 |
Manufacturing Services Agreement between the Registrant and Lonza Ltd. dated November 16, 2020 Exhibit 10.5 Manufacturing Services Agreement (the ?Agreement?) by and between Lonza Ltd M?nchensteinerstrasse 38 CH-4002 Basel Switzerland - hereinafter ?Lonza? - and Aurinia Pharmaceuticals Inc. 1203-4464 Markham Street Victoria BC V8Z 7X8 Canada - hereinafter ?Customer? - Effective as of November 16, 2020 (the ?Effective Date?) Certain identified information has been excluded from this exhibit |
|
| February 24, 2021 |
Employment Agreement between the Registrant and Stephen Robertson dated September 29, 2020 Exhibit 10.17 PERSONAL AND CONFIDENTIAL September 29, 2020 Stephen Robertson [redacted] Dear Stephen: Re: Executive Employment Agreement with Aurinia Pharmaceuticals Inc. We are pleased to offer you employment with Aurinia Pharmaceuticals Inc. (the "Company") as the Company's Executive Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer. This offer is subject to your |
|
| February 24, 2021 |
Employment Agreement between Aurinia Pharma U.S. Inc. and Joe Miller dated April 8, 2020 Exhibit 10.16 April 8, 2020 Joseph Miller [redacted] Re: Terms of Employment with Aurinia Pharma U.S., Inc. Dear Joseph: Aurinia Pharma U.S., Inc. (the "Company"), a Delaware Corporation and wholly owned subsidiary of Aurinia Pharmaceuticals Inc., a corporation under the laws of the Province of Alberta ("Parent"), is pleased to offer you employment as the Company's Chief Financial Officer ("CFO"), |
|
| February 24, 2021 |
S-8 1 auph-2021x02x24formsx8.htm S-8 As filed with the U.S. Securities and Exchange Commission on February 24, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aurinia Pharmaceuticals Inc. (Exact name of Registrant as specified in its charter) Alberta, Canada Not Applicable (State or |
|
| February 24, 2021 |
Form of Indemnity Agreement between the Registrant and each of its Directors and Executive Officers Exhibit 10.1 INDEMNITY AGREEMENT THIS AGREEMENT made as of the day of , 2020. BETWEEN: AURINIA PHARMACEUTICALS INC., a company incorporated under the laws of the Province of Alberta ("Aurinia") OF THE FIRST PART - and - (Fill in Name) (the "Executive") OF THE SECOND PART WHEREAS: A. The Executive is an officer and/or director of Aurinia or any subsidiary or affiliate (as those terms are defined in |
|
| February 24, 2021 |
Exhibit 10.9 EXECUTION VERSION SOFTGEL COMMERCIAL SUPPLY AGREEMENT (Voclosporin softgel capsules) This Softgel Commercial Supply Agreement ("Agreement") is made as of this 28th day of August 2020 ("Effective Date"), by and between Aurinia Pharmaceuticals Inc., an Alberta Canada corporation, with a place of business at 1203-4464 Markham St., Victoria, British Columbia V8Z 7X8, Canada ("Client"), an |
|
| February 24, 2021 |
Exhibit 10.10 Definitive Settlement Agreement ILJIN - ISOTECHNIKA - AURINA This tripartite Settlement agreement is made on April 3 2013 by and among Isotechnika Pharma Inc., incorporated pursuant to the laws of Alberta, Canada and having their principal office at 5120-751h St. Edmonton Alberta, Canada T6ER-6W2, ("ISOTECHNIKA") ILJIN Life Science Co. Ltd., a corporation, with its principal office a |
|
| February 24, 2021 |
Employment Agreement between Aurinia Pharma U.S. Inc. and Max Colao dated February 10, 2020 Exhibit 10.12 EMPLOYMENT AGREEMENT AURINIA PHARMA U.S., INC. PRIVATE AND CONFIDENTIAL February 10, 2020 Max Colao [redacted] Dear Max: Re: Terms of Employment with Aurinia Pharma U.S., Inc. This Employment Agreement ("Agreement'') sets forth the terms and conditions of your employment with Aurinia Pharma U.S., Inc. (the "Corporation "), a Delaware corporation and wholly owned subsidiary of Aurinia |
|
| February 24, 2021 |
Employment Agreement between Aurinia Pharma U.S. Inc. and Max Donley dated July 15, 2019 Exhibit 10.13 EMPLOYMENT AGREEMENT AURINIA PHARMA U.S., INC. PRIVATE AND CONFIDENTIAL July 15, 2019 Max Donley [redacted] Dear Max: Re: Terms of Employment with Aurinia Pharma U.S., Inc. This Employment Agreement (''Agreement'') sets forth the terms and conditions of your employment with Aurinia Pharma U.S., Inc. (the "Corporation"), a Delaware corporation and wholly owned subsidiary of Aurinia Ph |
|
| February 24, 2021 |
List of Subsidiaries of Registrant Exhibit 21.1 LIST OF SUBSIDIARIES The following is a list of subsidiaries of Aurinia Pharmaceuticals, Inc. as of December 31, 2020. Subsidiary State or Other Jurisdiction of Incorporation or Organization Aurinia Pharma U.S. Inc. Delaware Aurinia Pharma Limited United Kingdom |
|
| February 24, 2021 |
Description of the Registrant's Common Shares Exhibit 4.3 Description of Aurinia Pharmaceuticals Inc. Common Shares The following description of the authorized share capital of Aurinia Pharmaceuticals Inc. (Aurinia) is intended as a summary only. This summary is qualified in its entirety by reference to our amended certificate of amalgamation and our bylaws, both of which have been filed with the Securities and Exchange Commission and are inc |
|
| February 24, 2021 |
Form of Common Shares Certificate of the Company Exhibit 4.1 |
|
| February 24, 2021 |
Exhibit 99.2 Aurinia Pharmaceuticals Inc. Condensed Consolidated Balance Sheets (In thousands of United States dollars) (Unaudited) March 31, 2020 December 31, 2019 ASSETS Current assets Cash and cash equivalents $ 274,207 $ 306,019 Short term investments 11,913 ? Accrued interest and other receivables 3,513 368 Prepaid expenses and deposits 8,266 8,750 Total current assets 297,899 315,137 Non-cur |
|
| February 24, 2021 |
Exhibit 99.3 Aurinia Pharmaceuticals Inc. Condensed Consolidated Balance Sheets (In thousands of United States dollars) (Unaudited) June 30, 2020 December 31, 2019 ASSETS Current assets Cash and cash equivalents $ 232,414 $ 306,019 Short term investments 31,936 ? Accrued interest and other receivables 530 368 Prepaid expenses and deposits 13,161 8,750 Total current assets 278,041 315,137 Non-curre |
|
| February 24, 2021 |
Exhibit 99.4 Aurinia Pharmaceuticals Inc. Condensed Consolidated Balance Sheets (In thousands of United States dollars) (Unaudited) ASSETS September 30, 2020 December 31, 2019 Current assets Cash and cash equivalents $ 248,758 $ 306,019 Short term investments 143,268 ? Accrued interest and other receivables 1,129 368 Inventories 471 ? Prepaid expenses and deposits 11,714 8,750 Total current assets |
|
| February 24, 2021 |
Exhibit 99.1 AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS - LUPKYNISTM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - Cash, cash equivalents, and investments of $423 million at December 31, 2020 – - Con |
|
| February 24, 2021 |
Exhibit 10.7 OFFICE LEASE BETWEEN: TC EVOLUTION LIMITED PARTNERSHIP AND: AURINIA PHARMACEUTICALS INC. TABLE OF CONTENTS Page Part 1 DEFINITIONS/SCHEDULES 5 1.1 Defined Terms 5 1.2 Schedules 13 Part 2 INTENT 13 2.1 Net Lease 13 Part 3 PREMISES, TERM 13 3.1 Demise 13 Part 4 RENT AND ADDITIONAL RENT 13 4.1 Covenant to Pay Rent 13 4.2 Basic Rent 13 4.3 Certification of Rentable Area. 14 4.4 Additional |
|
| February 24, 2021 |
Employment Agreement between the Registrant and Robert Huizinga dated October 1, 2017 Exhibit 10.14 EXECUTIVE EMPLOYMENT AGREEMENT AURINIA PHARMACEUTICALS INC. PRIVATE AND CONFIDENTIAL October 1, 2017 Robert B. Huizinga [redacted] Dear Mr. Huizinga: Re: Terms of Employment with AURINIA PHARMACEUTICALS INC. (the ?Corporation?) This Agreement confirms the terms and conditions of your employment by the Corporation and will constitute your employment agreement. Those terms and conditio |
|
| February 24, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 AURINIA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 24, 2021 |
Employment Agreement between the Registrant and Neil Solomons dated October 1, 2017 Exhibit 10.18 EXECUTIVE EMPLOYMENT AGREEMENT AURINIA PHARMACEUTICALS INC. PRIVATE AND CONFIDENTIAL October 1, 2017 Neil Solomons [redacted] Dear Dr. Solomons: Re: Terms of Employment with AURINIA PHARMACEUTICALS INC. (the ?Corporation?) This Agreement confirms the terms and conditions of your employment by the Corporation and will constitute your employment agreement. Those terms and conditions ar |
|
| February 24, 2021 |
Exhibit 10.8 VANCOUVER ISLAND TECHNOLOGY PARK THIS LEASE, dated for reference this 30th day of October , 2020 is made by the Landlord and Tenant named below who, in consideration of the covenants in this Lease, agree as follows: 1. BASIC TERMS, SCHEDULES, AND DEFINITIONS 1.1 Basic Terms (a) Landlord: UNIVERSITY OF VICTORIA PROPERTIES INVESTMENTS INC. on behalf of the VANCOUVER ISLAND TECHNOLOGY PA |
|
| February 24, 2021 |
Separation Agreement between Aurinia Pharma U.S., Inc. and Erik Eglite dated October 26, 2020 Exhibit 10.19 October 26, 2020 Erik Eglite Via E-mail Re: Revised Transition and Separation Agreement Dear Erik: This letter sets forth the terms of the transition and separation agreement (the ?Agreement') that Aurinia Pharma U.S., Inc. (the "Company"), a Delaware corporation and a wholly owned subsidiary of Aurinia Pharmaceuticals Inc., a corporation under the laws of the Province of Alberta ("P |
|
| February 24, 2021 |
Form of Inducement Grant Option Commitment Exhibit 10.20 FORM OF OPTION COMMITMENT AURINIA PHARMACEUTICALS INC. OPTION COMMITMENT Notice is hereby given that, effective this ? day of ?, ? (the ?Effective Date?) AURINIA PHARMACEUTICALS INC. (the ?Company?) has granted to ? (the ?Service Provider?), an Option to acquire ? common shares of the Company (?Optioned Shares?) up to ? p.m. MT on the ? day of ?, ? (the ?Expiry Date?) at an exercise |
|
| February 24, 2021 |
Exhibit 3.1 |
|
| February 24, 2021 |
Exhibit 10.6 OFFICE LEASE between BOF II MD 77 UPPER ROCK LLC, (Landlord) and AURINIA PHARMA U.S., INC. (Tenant) 77 UPPER ROCK CIRCLE Rockville, Maryland Certain identified information has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. OFFICE LEASE INDEX SECTION PAGE 1. LEASED PREMISES. 1 2. TERM. 1 3. acceptance o |
|
| February 24, 2021 |
Employment Agreement between the Registrant and Michael Martin dated October 1, 2017 Exhibit 10.15 EXECUTIVE EMPLOYMENT AGREEMENT AURINIA PHARMACEUTICALS INC. PRIVATE AND CONFIDENTIAL October 1, 2017 Michael Robert Martin [redacted] Dear Mr. Martin: Re: Terms of Employment with AURINIA PHARMACEUTICALS INC. (the ?Corporation?) This Agreement confirms the terms and conditions of your employment by the Corporation and will constitute your employment agreement. Those terms and conditi |
|
| February 24, 2021 |
Employment Agreement between Aurinia Pharma U.S., Inc. and Peter Greenleaf dated April 11, 2019 Exhibit 10.11 EXECUTIVE EMPLOYMENT AGREEMENT AURINIA PHARMA U.S., INC. PRIVATE AND CONFIDENTIAL April 11, 2019 Peter Greenleaf [redacted] Dear Peter: Re: Terms of Employment with Aurinia Pharma U.S., Inc. This Agreement confirms the terms and conditions of your employment by Aurinia Pharma U.S., Inc. (the ?Corporation?), a Delaware corporation and a wholly-owned subsidiary of Aurinia Pharmaceutica |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36421 Aurinia Pharmaceuticals I |
|
| February 17, 2021 |
SC 13G/A 1 aupha121621.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AURINIA PHARMACEUTICALS INC (Name of Issuer) Common stock, no par value per share (Title of Class of Securities) 05156V102 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing o |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AURINIA PHARMACEUTICALS INC (Name of Issuer) Common stock, no par value per share (Title of Class of Securities) 05156V102 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 12, 2021 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 12, 2021 |
SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Aurinia Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05156V102 (CUSIP Number) December 31, 2020 (Date of Event Which Requ |
|
| January 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13D-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 10) Aurinia Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 05156V102 (CUSIP Numb |
|
| January 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13D-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 9) Aurinia Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 05156V102 (CUSIP Numbe |
|
| January 25, 2021 |
prfdaapprovalforlupkynis NEWS RELEASE FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis - LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - LUPKYNIS demonstrated significantly improved renal response rates compared to typical standard-of-care (SoC) in clinical trials - LUPKYNIS is now commercially available in the U. |
|
| January 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 AURINIA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-36421 46-4129078 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 25, 2021 |
auriniainvestorpresentat Changing the Course of Autoimmune Disease LUPKYNIS™ FDA Approval and Launch January 25, 2021 Cautionary Statement regarding Forward-Looking Information 4/7/20 2 Certain statements made in this slide presentation may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable United States securities law. |
|
| December 30, 2020 |
Exhibit 99.2 COLLABORATION AND LICENSE Agreement by and between AURINIA PHARMACEUTICALS INC. and OTSUKA PHARMACEUTICAL CO., LTD. DECEMBER 17, 2020 Table of Contents Page 1. DEFINITIONS 1 2. LICENSES; RIGHTS; EXCLUSIVITY 21 2.1 License Grants to Otsuka 21 2.2 License Grants to Aurinia 22 2.3 Retained Rights 23 2.4 Access to Sublicensee Work Product 23 2.5 No Implied Licenses; Negative Covenant 25 2 |
|
| December 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated December 30, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Vict |
|
| December 30, 2020 |
FORM 51-102F3 Material Change Report FORM 51-102F3 Material Change Report Exhibit 99.1 Item 1 Name and Address of Company Aurinia Pharmaceuticals Inc. (the "Company") #1203-4464 Markham Street Victoria, BC V8Z 7X8 Canada Item 2 Date of Material Change December 17, 2020 Item 3 News Release A news release was issued and disseminated by the Company through Business News Wire on December 17, 2020. Item 4 Summary of Material Change On Dec |
|
| December 21, 2020 |
Exhibit 99.1 Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan - Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments - - Agreement includes royalties of up to 20 percent on net sales payable |
|
| December 21, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated December 17, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Vict |
|
| December 16, 2020 |
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity Exhibit 99.1 Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity - State-of-the-Art Monoplant Will Provide Cost and Production Efficiency and Secure Active Pharmaceutical Ingredient (API) Supply for Future Commercial Demand - VICTORIA, British Columbia-(BUSINESS WIRE)-December 15, 2020-Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) an |
|
| December 16, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated December 15, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Vict |
|
| November 20, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 20, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Vict |
|
| November 20, 2020 |
Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Exhibit 99.1 Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) VICTORIA, British Columbia-(BUSINESS WIRE)-November 20, 2020-Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that the Company’s Compensation Committee granted the newly appointed Executive Vice Presid |
|
| November 10, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, PETER GREENLEAF, Chief Executive Officer of AURINIA PHARMACEUTICALS Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A, (together, the ?interim filings?) of Aurinia Pharmaceuticals Inc. (the ?issuer?) for the interim period ended September 30, 2020. 2. No misrepresenta |
|
| November 10, 2020 |
Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights Exhibit 99.1 Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights - U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of January 22, 2021 - - Cash, cash equivalents and investments totaled approximately $421 million at September 30, 2020 - - Conference call and webcast to be hosted today at 4:30pm EDT - VICTORIA, British Co |
|
| November 10, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K 6-K 1 a52324358.htm AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 10, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation |
|
| November 10, 2020 |
Exhibit 99.2 Management's Discussion and Analysis Third Quarter Ended September 30, 2020 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2020 In this Management?s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), unless the context otherwise requires, references to "we", "us", "our" or |
|
| November 10, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, JOSEPH MILLER, Chief Financial Officer of AURINIA PHARMACEUTICALS Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A, (together, the ?interim filings?) of Aurinia Pharmaceuticals Inc. (the ?issuer?) for the interim period ended September 30, 2020. 2. No misrepresentati |
|
| November 10, 2020 |
EX-99.1 2 exhibit991-20200930interim.htm EXHIBIT 99.1 Exhibit 99.1 Financial Statements Third Quarter Ended September 30, 2020 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at September 30, 2020 (expressed in thousands of US dollars) September 30, 2020 $ December 31, 2019 $ Assets Current assets Cash and cash equivalents 248,758 306,019 |
|
| November 10, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 10, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant's Name) #1203-4464 Markham Street Vict |
|
| November 9, 2020 |
Exhibit 99.1 Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020 - Integrated analysis confirms addition of voclosporin to standard-of-care resulted in faster Renal Response compared to standard-of-care alone in lupus nephritis - - DDI study demonstrates no clinically meaningful intera |
|
| November 9, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 9, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Victo |
|
| November 2, 2020 |
Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome EX-99.1 2 a52318949ex991.htm EXHIBIT 99.1 Exhibit 99.1 Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome - The trial did not achieve statistical significance on the primary endpoint of ≥ 10mm improvement in Schirmer Tear Test (STT) at 4 weeks – - Company to suspend development program for voclosporin ophthalmic solution (VOS) - - Aurinia to host conference call today at 4:30 |
|
| November 2, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 2, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Victo |
|
| October 29, 2020 |
Exhibit 99.1 Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19 VICTORIA, British Columbia-(BUSINESS WIRE)-October 27, 2020-Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple |
|
| October 29, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 27, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Victo |
|
| October 22, 2020 |
Exhibit 99.1 Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020 - Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care – - Voclosporin pharmacokinetic data supports consistent dose-response, potentially elimin |
|
| October 22, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 22, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Victo |
|
| October 14, 2020 |
Exhibit 99.1 Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com VICTORIA, British Columbia-(BUSINESS WIRE)-October 14, 2020-Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced Time Is Nephrons, the first-ever lupus nephritis (LN) disease-state awareness campaig |
|
| October 14, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 14, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Victo |
|
| October 9, 2020 |
CA:AUP / Aurinia Pharmaceuticals Inc / ILJIN SNT Co., Ltd. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13D-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 8) Aurinia Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 05156V102 (CUSIP Numbe |
|
| October 2, 2020 |
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Exhibit 99.1 Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VICTORIA, British Columbia-(BUSINESS WIRE)-October 2, 2020-Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Com |
|
| October 2, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated October 2, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Victor |
|
| September 28, 2020 |
Exhibit 99.1 Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome - Voclosporin ophthalmic solution (VOS) results on track to be reported in the fourth quarter of 2020 - - Study builds on positive head-to-head data with approved treatment reported in prior Phase 2a study - - Dry eye syndrome is a chronic autoimmune dis |
|
| September 28, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated September 28, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Vic |
|
| September 8, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated September 4, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Vict |
|
| September 8, 2020 |
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Exhibit 99.1 Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VICTORIA, British Columbia & ROCKVILLE, Md.-(BUSINESS WIRE)-September 4, 2020-Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company |
|
| August 11, 2020 |
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights Exhibit 99.1 Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights - U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of January 22, 2021 - - Cash, cash equivalents and short term investments totaled approximately $442.06 million at July 31, 2020 - - Conference call and webcast to be hosted today at 4:30pm EDT - VICTORIA, |
|
| August 11, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, PETER GREENLEAF, Chief Executive Officer of AURINIA PHARMACEUTICALS Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A, (together, the “interim filings”) of Aurinia Pharmaceuticals Inc. (the “issuer”) for the interim period ended June 30,2020. 2. No misrepresentations: |
|
| August 11, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated August 11, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant's Name) #1203-4464 Markham Street Victor |
|
| August 11, 2020 |
Current Report of Foreign Issuer - AURINIA PHARMACEUTICALS INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated August 11, 2020 Commission File Number 001-36421 AURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant’s Name) #1203-4464 Markham Street Victor |
|
| August 11, 2020 |
Exhibit 99.1 Financial Statements Second Quarter Ended June 30, 2020 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at June 30, 2020 (expressed in thousands of US dollars) June 30, 2020 $ December 31, 2019 $ Assets Current assets Cash and cash equivalents 232,414 306,019 Short term investments (note 4) 31,936 — Accrued interest and other |
